Risk-stratification is a crucial component in the management of patients with myelodysplastic syndromes (MDS), with survival rates varying from a few months to over a decade and a broad spectrum or treatment approaches available, ranging from observation or transfusions, to chemotherapy or bone marrow transplantation. Patients with MDS are classified into very low-, low-, intermediate-, high- and very high-risk disease categories using prognostic scoring systems such as the International Prognostic Scoring System-Revised (IPSS-R). The IPSS-R incorporates bone marrow cytogenetics, blast percentage, and peripheral blood cytopenia.
The use of prognostic scoring systems in the management of malignancies is commonplace; however, these are usually based on retrospective data from patients who underwent heterogeneous treatment approaches, and as such often fail to encompass all available prognostic information at an individual patient level. Furthermore, the rapid development of high throughput technologies such as next-generation sequencing has identified multiple mutations with roles in MDS, including TET2, SF3B1, ASXL1, SRSF2, DNMT3A, and RUNX1, many of which have been shown to have prognostic value.
This collection aims to collate research which can contribute to improved risk-stratification for patients with MDS in order to optimize clinical decision-making and subsequent survival outcomes for patients, as well as to prevent unnecessary treatment in lower-risk patients.
Please note: manuscripts that are solely based on bioinformatics or computational analysis of public databases without validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Risk-stratification is a crucial component in the management of patients with myelodysplastic syndromes (MDS), with survival rates varying from a few months to over a decade and a broad spectrum or treatment approaches available, ranging from observation or transfusions, to chemotherapy or bone marrow transplantation. Patients with MDS are classified into very low-, low-, intermediate-, high- and very high-risk disease categories using prognostic scoring systems such as the International Prognostic Scoring System-Revised (IPSS-R). The IPSS-R incorporates bone marrow cytogenetics, blast percentage, and peripheral blood cytopenia.
The use of prognostic scoring systems in the management of malignancies is commonplace; however, these are usually based on retrospective data from patients who underwent heterogeneous treatment approaches, and as such often fail to encompass all available prognostic information at an individual patient level. Furthermore, the rapid development of high throughput technologies such as next-generation sequencing has identified multiple mutations with roles in MDS, including TET2, SF3B1, ASXL1, SRSF2, DNMT3A, and RUNX1, many of which have been shown to have prognostic value.
This collection aims to collate research which can contribute to improved risk-stratification for patients with MDS in order to optimize clinical decision-making and subsequent survival outcomes for patients, as well as to prevent unnecessary treatment in lower-risk patients.
Please note: manuscripts that are solely based on bioinformatics or computational analysis of public databases without validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
